Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax® , as a therapeutic strategy for metastatic breast cancer.
Nov 29, 2014 .. .. The frequencies of activated NK, CD4+ and CD8+ cells as well as myeloid-derived suppressor cells and Treg cells were evaluated using flow cytometry. Highly purified mouse and human dendritic and NK cells were sorted and the effect of Immunomax® on activation status of these cells was assessed by flow cytometry. .. ..
Conclusion
This is the first demonstration that Immunomax® is a TLR-4 agonist and the first report of a documented role for this pharmaceutical grade immunostimulator in augmenting anti-tumor activity, suggesting that incorporation of Immunomax® into developing breast cancer therapeutic strategies may be beneficial and with less potential toxicity than checkpoint inhibitors.
Interesting, this article seems to say that checkpoint inhibitors have toxicity but they certainly are not talking about the only upstream PS Targeting drugs such as Bavituximab, so another combination with Bavi is possible here?
Market Data 
Markets 
AI
